Europe Cephalosporin Drugs Market (2019-2025)
The Europe Cephalosporin Drugs Market would witness market growth of 2.94% CAGR during the forecast period (2019–2025).
Cephalosporin Drugs is a bactericidal, wide-spectrum, β-lactam antibiotic initially extracted from the Acremonium fungus that is used to treat bacterial diseases such as pneumonia, skin diseases, tonsillitis, otitis media, bronchitis, gonorrhea, and others. It is similar to penicillin and is, therefore, used as an option to penicillin-allergic patients.
Developing extremely effective and secure Cephalosporin Drugs, growing mergers and corporate acquisitions to manufacturing these drugs are likely to create growth opportunities for the market for Cephalosporin Drugs in the coming years. On the other hand, low R&D investment and rigid public policies on these medicines hamper the market growth.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
Cephalosporin Drugs is a bactericidal, wide-spectrum, β-lactam antibiotic initially extracted from the Acremonium fungus that is used to treat bacterial diseases such as pneumonia, skin diseases, tonsillitis, otitis media, bronchitis, gonorrhea, and others. It is similar to penicillin and is, therefore, used as an option to penicillin-allergic patients.
Developing extremely effective and secure Cephalosporin Drugs, growing mergers and corporate acquisitions to manufacturing these drugs are likely to create growth opportunities for the market for Cephalosporin Drugs in the coming years. On the other hand, low R&D investment and rigid public policies on these medicines hamper the market growth.
Based on Generation, the market is segmented into First-Generation Cephalosporin, Second-Generation Cephalosporin, Third-Generation Cephalosporin, Fourth-Generation Cephalosporin, and Fifth-Generation Cephalosporin. Based on Application, the market is segmented into Respiratory Tract Infection, Skin Infection, Ear Infection, Sexually Transmitted Infection and Others. Based on Route of Administration, the market is segmented into Injections and Oral Drugs. Based on Type, the market is segmented into Branded and Generic. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report ABBOTT Laboratories, Teva Pharmaceuticals Industries Ltd., Johnson and Johnson, GlaxoSmithKline PLC (GSK), Pfizer, Inc., Merck & Co., Inc., Bayer AG, Baxter International, Inc., Bristol-Myers Squibb Company and Novartis AG.
Scope of the Study
Market Segmentation:
By Generation
- First-Generation Cephalosporin
- Second-Generation Cephalosporin
- Third-Generation Cephalosporin
- Fourth-Generation Cephalosporin
- Fifth-Generation Cephalosporin
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Sexually Transmitted Infection
- Others
- Injections
- Oral Drugs
- Branded
- Generic
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- ABBOTT Laboratories
- Teva Pharmaceuticals Industries Ltd.
- Johnson and Johnson
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Merck & Co., Inc.
- Bayer AG
- Baxter International, Inc.
- BRISTOL-MYERS SQUIBB COMPANY
- Novartis AG
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Cephalosporin Drugs Market, by Generation
1.4.2 Europe Cephalosporin Drugs Market, by Application
1.4.3 Europe Cephalosporin Drugs Market, by Route of Administration
1.4.4 Europe Cephalosporin Drugs Market, by Type
1.4.5 Europe Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 Europe First-Generation Cephalosporin Drugs Market by Country
3.2 Europe Second-Generation Cephalosporin Drugs Market by Country
3.3 Europe Third-Generation Cephalosporin Drugs Market by Country
3.4 Europe Fourth-Generation Cephalosporin Drugs Market by Country
3.5 Europe Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 Europe Respiratory Tract Infection Market by Country
4.2 Europe Skin Infection Market by Country
4.3 Europe Ear Infection Market by Country
4.4 Europe Sexually Transmitted Infection Market by Country
4.5 Europe Others Market by Country
CHAPTER 5. EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 Europe Injections Market by Country
5.2 Europe Oral Drugs Market by Country
CHAPTER 6. EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 Europe Branded Market by Country
6.2 Europe Generic Market by Country
CHAPTER 7. EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 Germany Cephalosporin Drugs Market
7.1.1 Germany Cephalosporin Drugs Market by Generation
7.1.2 Germany Cephalosporin Drugs Market by Application
7.1.3 Germany Cephalosporin Drugs Market by Route of Administration
7.1.4 Germany Cephalosporin Drugs Market by Type
7.2 UK Cephalosporin Drugs Market
7.2.1 UK Cephalosporin Drugs Market by Generation
7.2.2 UK Cephalosporin Drugs Market by Application
7.2.3 UK Cephalosporin Drugs Market by Route of Administration
7.2.4 UK Cephalosporin Drugs Market by Type
7.3 France Cephalosporin Drugs Market
7.3.1 France Cephalosporin Drugs Market by Generation
7.3.2 France Cephalosporin Drugs Market by Application
7.3.3 France Cephalosporin Drugs Market by Route of Administration
7.3.4 France Cephalosporin Drugs Market by Type
7.4 Russia Cephalosporin Drugs Market
7.4.1 Russia Cephalosporin Drugs Market by Generation
7.4.2 Russia Cephalosporin Drugs Market by Application
7.4.3 Russia Cephalosporin Drugs Market by Route of Administration
7.4.4 Russia Cephalosporin Drugs Market by Type
7.5 Spain Cephalosporin Drugs Market
7.5.1 Spain Cephalosporin Drugs Market by Generation
7.5.2 Spain Cephalosporin Drugs Market by Application
7.5.3 Spain Cephalosporin Drugs Market by Route of Administration
7.5.4 Spain Cephalosporin Drugs Market by Type
7.6 Italy Cephalosporin Drugs Market
7.6.1 Italy Cephalosporin Drugs Market by Generation
7.6.2 Italy Cephalosporin Drugs Market by Application
7.6.3 Italy Cephalosporin Drugs Market by Route of Administration
7.6.4 Italy Cephalosporin Drugs Market by Type
7.7 Rest of Europe Cephalosporin Drugs Market
7.7.1 Rest of Europe Cephalosporin Drugs Market by Generation
7.7.2 Rest of Europe Cephalosporin Drugs Market by Application
7.7.3 Rest of Europe Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of Europe Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Cephalosporin Drugs Market, by Generation
1.4.2 Europe Cephalosporin Drugs Market, by Application
1.4.3 Europe Cephalosporin Drugs Market, by Route of Administration
1.4.4 Europe Cephalosporin Drugs Market, by Type
1.4.5 Europe Cephalosporin Drugs Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION
3.1 Europe First-Generation Cephalosporin Drugs Market by Country
3.2 Europe Second-Generation Cephalosporin Drugs Market by Country
3.3 Europe Third-Generation Cephalosporin Drugs Market by Country
3.4 Europe Fourth-Generation Cephalosporin Drugs Market by Country
3.5 Europe Fifth-Generation Cephalosporin Drugs Market by Country
CHAPTER 4. EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION
4.1 Europe Respiratory Tract Infection Market by Country
4.2 Europe Skin Infection Market by Country
4.3 Europe Ear Infection Market by Country
4.4 Europe Sexually Transmitted Infection Market by Country
4.5 Europe Others Market by Country
CHAPTER 5. EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION
5.1 Europe Injections Market by Country
5.2 Europe Oral Drugs Market by Country
CHAPTER 6. EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE
6.1 Europe Branded Market by Country
6.2 Europe Generic Market by Country
CHAPTER 7. EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY
7.1 Germany Cephalosporin Drugs Market
7.1.1 Germany Cephalosporin Drugs Market by Generation
7.1.2 Germany Cephalosporin Drugs Market by Application
7.1.3 Germany Cephalosporin Drugs Market by Route of Administration
7.1.4 Germany Cephalosporin Drugs Market by Type
7.2 UK Cephalosporin Drugs Market
7.2.1 UK Cephalosporin Drugs Market by Generation
7.2.2 UK Cephalosporin Drugs Market by Application
7.2.3 UK Cephalosporin Drugs Market by Route of Administration
7.2.4 UK Cephalosporin Drugs Market by Type
7.3 France Cephalosporin Drugs Market
7.3.1 France Cephalosporin Drugs Market by Generation
7.3.2 France Cephalosporin Drugs Market by Application
7.3.3 France Cephalosporin Drugs Market by Route of Administration
7.3.4 France Cephalosporin Drugs Market by Type
7.4 Russia Cephalosporin Drugs Market
7.4.1 Russia Cephalosporin Drugs Market by Generation
7.4.2 Russia Cephalosporin Drugs Market by Application
7.4.3 Russia Cephalosporin Drugs Market by Route of Administration
7.4.4 Russia Cephalosporin Drugs Market by Type
7.5 Spain Cephalosporin Drugs Market
7.5.1 Spain Cephalosporin Drugs Market by Generation
7.5.2 Spain Cephalosporin Drugs Market by Application
7.5.3 Spain Cephalosporin Drugs Market by Route of Administration
7.5.4 Spain Cephalosporin Drugs Market by Type
7.6 Italy Cephalosporin Drugs Market
7.6.1 Italy Cephalosporin Drugs Market by Generation
7.6.2 Italy Cephalosporin Drugs Market by Application
7.6.3 Italy Cephalosporin Drugs Market by Route of Administration
7.6.4 Italy Cephalosporin Drugs Market by Type
7.7 Rest of Europe Cephalosporin Drugs Market
7.7.1 Rest of Europe Cephalosporin Drugs Market by Generation
7.7.2 Rest of Europe Cephalosporin Drugs Market by Application
7.7.3 Rest of Europe Cephalosporin Drugs Market by Route of Administration
7.7.4 Rest of Europe Cephalosporin Drugs Market by Type
CHAPTER 8. COMPANY PROFILES
8.1 ABBOTT Laboratories
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.1 Recent strategies and developments:
8.1.1.1 Collaborations, partnerships and agreements:
8.1.1.2 Acquisition and Mergers:
8.2 Teva Pharmaceutical Industries Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Product launches:
8.3 Johnson and Johnson
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental &Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Acquisition and Mergers:
8.4 GlaxoSmithKline PLC (GSK)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Collaborations, partnerships and agreements:
8.4.5.2 Expansion:
8.4.5.3 Approval:
8.5 Pfizer, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expense
8.5.5 Recent strategies and developments:
8.5.5.1 Collaborations, partnerships and agreements:
8.5.5.2 Product launches:
8.5.5.3 Acquisition and Mergers:
8.6 Merck & Co., Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Collaborations, partnerships and agreements:
8.6.5.2 Product launches:
8.7 Bayer AG (Bayer Schering Pharma AG)
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 Recent strategies and developments:
8.7.5.1 Collaborations, partnerships and agreements:
8.7.5.2 Product launches:
8.8 Baxter International, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Product launches:
8.9 Bristol-Myers Squibb Company
8.9.1 Company overview
8.9.2 Financial Analysis
8.9.3 Regional Analysis
8.9.4 Research & Development Expense
8.9.5 Recent strategies and developments:
8.9.5.1 Collaborations, partnerships and agreements:
8.1 Novartis AG
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Product launches:
8.10.5.2 Acquisition and Mergers:
LIST OF TABLES
TABLE 1 EUROPE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 EUROPE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 EUROPE FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 EUROPE FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 EUROPE SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 EUROPE SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 EUROPE THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 EUROPE THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 EUROPE FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 EUROPE FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 EUROPE FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 EUROPE FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 EUROPE RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 EUROPE RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 EUROPE SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 EUROPE SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 EUROPE EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 EUROPE EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 EUROPE SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 EUROPE SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 EUROPE OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 EUROPE OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 EUROPE INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 EUROPE INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 EUROPE ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 EUROPE ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 EUROPE BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 EUROPE BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 EUROPE GENERIC MARKET BY COUNTRY, 2015 - 2018,USD MILLION
TABLE 38 EUROPE GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 GERMANY CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 GERMANY CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 GERMANY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 GERMANY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 GERMANY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 GERMANY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 GERMANY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 GERMANY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 GERMANY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 GERMANY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 UK CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 UK CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 UK CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 UK CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 UK CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 UK CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 UK CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 UK CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 UK CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 UK CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 FRANCE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 FRANCE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 FRANCE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 FRANCE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 FRANCE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 FRANCE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 FRANCE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 FRANCE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 FRANCE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 FRANCE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 RUSSIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 RUSSIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 RUSSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 RUSSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 RUSSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 RUSSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 RUSSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 RUSSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 RUSSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 RUSSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 SPAIN CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 82 SPAIN CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 83 SPAIN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 84 SPAIN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 85 SPAIN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 86 SPAIN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 87 SPAIN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 88 SPAIN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 89 SPAIN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 90 SPAIN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 91 ITALY CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 92 ITALY CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 93 ITALY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 94 ITALY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 95 ITALY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 ITALY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 ITALY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 98 ITALY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 99 ITALY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 100 ITALY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 101 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 102 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 103 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 104 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 105 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 106 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 107 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 108 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 109 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 110 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 111 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 112 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 113 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 114 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 115 KEY INFORMATION – PFIZER, INC.
TABLE 116 KEY INFORMATION – MERCK & CO., INC.
TABLE 117 KEY INFORMATION – BAYER AG
TABLE 118 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 119 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 120 KEY INFORMATION – NOVARTIS AG
TABLE 1 EUROPE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 2 EUROPE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 3 EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 4 EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 5 EUROPE FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 6 EUROPE FIRST-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 7 EUROPE SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 8 EUROPE SECOND-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 9 EUROPE THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 10 EUROPE THIRD-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 11 EUROPE FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 12 EUROPE FOURTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 13 EUROPE FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 14 EUROPE FIFTH-GENERATION CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 15 EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 16 EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 17 EUROPE RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 18 EUROPE RESPIRATORY TRACT INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 19 EUROPE SKIN INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 20 EUROPE SKIN INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 21 EUROPE EAR INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 22 EUROPE EAR INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 23 EUROPE SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 24 EUROPE SEXUALLY TRANSMITTED INFECTION MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 25 EUROPE OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 26 EUROPE OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 27 EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 28 EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 29 EUROPE INJECTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 30 EUROPE INJECTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 31 EUROPE ORAL DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 32 EUROPE ORAL DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 33 EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 34 EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 35 EUROPE BRANDED MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 36 EUROPE BRANDED MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 37 EUROPE GENERIC MARKET BY COUNTRY, 2015 - 2018,USD MILLION
TABLE 38 EUROPE GENERIC MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 39 EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2015 - 2018, USD MILLION
TABLE 40 EUROPE CEPHALOSPORIN DRUGS MARKET BY COUNTRY, 2019 - 2025, USD MILLION
TABLE 41 GERMANY CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 42 GERMANY CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 43 GERMANY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 44 GERMANY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 45 GERMANY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 46 GERMANY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 47 GERMANY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 48 GERMANY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 49 GERMANY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 50 GERMANY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 51 UK CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 52 UK CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 53 UK CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 54 UK CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 55 UK CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 56 UK CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 57 UK CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 58 UK CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 59 UK CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 60 UK CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 61 FRANCE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 62 FRANCE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 63 FRANCE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 64 FRANCE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 65 FRANCE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 66 FRANCE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 67 FRANCE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 68 FRANCE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 69 FRANCE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 70 FRANCE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 71 RUSSIA CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 72 RUSSIA CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 73 RUSSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 74 RUSSIA CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 75 RUSSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 76 RUSSIA CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 77 RUSSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 78 RUSSIA CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 79 RUSSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 80 RUSSIA CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 81 SPAIN CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 82 SPAIN CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 83 SPAIN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 84 SPAIN CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 85 SPAIN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 86 SPAIN CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 87 SPAIN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 88 SPAIN CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 89 SPAIN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 90 SPAIN CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 91 ITALY CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 92 ITALY CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 93 ITALY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 94 ITALY CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 95 ITALY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 96 ITALY CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 97 ITALY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 98 ITALY CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 99 ITALY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 100 ITALY CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 101 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET, 2015 - 2018, USD MILLION
TABLE 102 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET, 2019 - 2025, USD MILLION
TABLE 103 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2015 - 2018, USD MILLION
TABLE 104 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY GENERATION, 2019 - 2025, USD MILLION
TABLE 105 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2015 - 2018, USD MILLION
TABLE 106 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY APPLICATION, 2019 - 2025, USD MILLION
TABLE 107 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2015 - 2018, USD MILLION
TABLE 108 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2019 - 2025, USD MILLION
TABLE 109 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2015 - 2018, USD MILLION
TABLE 110 REST OF EUROPE CEPHALOSPORIN DRUGS MARKET BY TYPE, 2019 - 2025, USD MILLION
TABLE 111 KEY INFORMATION – ABBOTT LABORATORIES
TABLE 112 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 113 KEY INFORMATION –JOHNSON AND JOHNSON
TABLE 114 KEY INFORMATION – GLAXOSMITHKLINE PLC (GSK)
TABLE 115 KEY INFORMATION – PFIZER, INC.
TABLE 116 KEY INFORMATION – MERCK & CO., INC.
TABLE 117 KEY INFORMATION – BAYER AG
TABLE 118 KEY INFORMATION – BAXTER INTERNATIONAL, INC.
TABLE 119 KEY INFORMATION – BRISTOL-MYERS SQUIBB COMPANY
TABLE 120 KEY INFORMATION – NOVARTIS AG
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
